VOV.VN - The country is poised to get the second part of human trials for the COVIVAX novel coronavirus (COVID-19) vaccine underway in early January, with the vaccine notable for being developed locally by the Institute of Vaccines and Medical Biologicals (IVAC).
At present, local vaccine manufacturers nationwide are in the process of speeding up the research stage to carry out clinical human trials on two vaccines, namely COVIVAX and Nanocovax.
Most notably, the Nanocovax vaccine, which has been developed by Nanogen Pharmaceutical Biotechnology JSC, has already gone through the first clinical phase, with volunteers set to receive their second shot on January 14.
The second phase of the local clinical human trials will start immediately after the Lunar New Year, known locally as Tet, with two doses being given on volunteers.
The second vaccine, COVIVAX, has been submitted to Ministry of Health who have granted approval for human trials to be conducted in January.
Providing that the clinical trial results prove successful, the vaccine can then be sold in the domestic market in the second quarter of the year.
Vietnam is one of 40 countries globally that have conducted clinical human trials on a COVID-19 vaccine.